Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — Investor Presentation (November 2016)
31 slides from Rpg Life Sciences's investor presentation, Nov 15, 2016
Slide 1: Exchange Disclosure Letter
RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: 4+91-22-25292152.55 @ Fax; +91-22-25297423 November 15, 2016 The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limite
Slide 2: Investor Presentation
Investor Presentation November 15, 2016
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: Table of Contents
Table of Contents RPG Group RPG LS : Overview, Performance and Strategic Direction RPG LS : Financials
Slide 5: RPG Group: Powered by Passion, Driven by Ethics
RPG RPG LIFE SCIENCES LIMITED RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979 by Shri Rama Prasad Goenka, popularly UNLEASHTALENT known as RP Goenka, a pioneering fifth generation business leader from the TOUCH LIVES Goenka family. The Goenkas have a history of bu
Slide 6: RPG Group: Key Financials
RPG LIFE SCIENCES LIMITED RPG RPG Group: Key Financials wine mNet Revenue (Rs Cr) tases te761 EBITDA (Rs Cr) mPAT (Rs Cr) CAGR: 12% 17,614 - FY11-16 CAGR: 2,080 15,788 EBITDA 17% PAT 19% 13,962 1,690 1,731 1,250 1,117 030 714 795 429 404 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 16,000 > ME
Slide 7: Table of Contents
Table of Contents RPG Group RPG LS : Overview, Performance and Strategic Direction RPG LS : Financials
Slide 8: RPG LS: Business Overview
RPG LS: Business Overview Our Business Segments Location: Head Office in Mumbai • Dosage Forms Manufacturing Locations: Navi • Emerging Mumbai & Ankleshwar International • Regulated markets Formulations Distribution Spread: 19 CFA’s and 19% 1400 stockiest R&D: DSIR approved R&D centre at Nav
Slide 9: RPGLS Management Team
RPGLS-Management Team CT. Renganathan Managing Director BM Sundaram Rajib Das Satessh Siingh Dr. Uday Bapat Mahesh Nitin Gore Suchitra Tiwari Ninad Rawle Head – International VP- Sales & Marketing VP - Sales & Business Chief Scientific Narayanaswamy Chief Quality Officer Head- Regulatory & Head Proc
Slide 10: RPG LS: Board of Directors
RPG LS: Board of Directors Name Designation Harsh Vardhan Goenka Chairman & Non-Executive Director CT. Renganathan Managing Director Sachin Nandgaonkar Non Executive Director & Non – Independent Director C.L. Jain Non Executive Non Independent Director Dr. Lalit Kanodia Non Executive Non Independent
Slide 11: RPG LS: Manufacturing Facilities
RPG LS: Manufacturing Facilities Ankleshwar, Gujarat - Formulation Plant F 1 (WHO Approved) - Formulation Plant F2 (EUGMP ) Navi Mumbai, Maharashtra - API Plant – EUGMP/TGA/WHO approved Operational 10
Slide 12: FY16: Good beginning, lot of headroom
FY 16: Good beginning, lot of headroom FY 15 FY 16 Rs Cr Rs Cr Growth Sales 233 275 18% PAT 1 11 1000% PAT % 0.4% 4% EPS 0.6 7.0 1067% Share Price 63-123 140-342 159% M Cap 104-203 232-566 160% Actions underway to build a 1000 Crs business 11
Slide 13: Strategic Direction Going Forward
Strategic Direction Going Forward Portfolio Rationalization Domestic Business Growth International Formulation Business Growth 12
Slide 14: Portfolio Rationalization
Portfolio Rationalization To be at higher end of the value chain; focus on formulation domestic and international markets Synthetic API would be majorly captive support to formulation Biotech API unit hived off. Proceeds to be used to grow formulations business 13
Slide 15: Domestic Formulations business is back on a growth trajectory
Domestic Formulations business is back on a growth trajectory 167.7 18% Sales (Rs Cr) 143.3 135.1 136.2 17% 15% 126.5 Growth % 106.8 7% 5% 1% FY11 FY12 FY13 FY14 FY15 FY16 Ranking has improved to 19th fastest growing Ranked as 1st in 68th rank from 73rd in the company among Top 100 Immunosuppressant
Slide 16: Main Division: Focus Brands
Main Division: Focus Brands Therapy : Antacid Sales grew by 32 % to Rs.12 cr. 2nd largest brand in represented therapy Therapy : Vitamins and Iron supplement Sales grew by 90 % to Rs 8 cr. 12 nd largest brand in represented therapy Therapy : Antacid Sales grew by 16 % to Rs 4 cr. 15
Slide 17: Main Division: Growth in Legacy Brands
Main Division : Growth in Legacy Brands Therapy : Anti Diarrhoeal Sales grew by 38 % to Rs 17.94 cr. Therapy : CNS Sales grew by 16 % to Rs 9 cr. Therapy : Diuretic Sales grew by 37 % to Rs 19 cr. 16
Slide 18: Main: New Product Introductions
Main: New Product Introductions Therapy : Platelet Booster Launched in Dec 2015. Sales clocked Rs 1 cr. Therapy : Pain Management Launched in Jan 16 . Sales clocked Rs 0.20 cr. 17
Slide 19: Main Division: New Product Launches
Main Division: New Product Launches • Restores natural vaginal • PH Hygiene Partner • Quick and Safe antidiarrhoeal moisture with added advantage • Encash brand equity of • Increases intimacy of Cranberry Lomofen • Patented formulation • Prevention & treatment • Snatch the market through • Hormone f
Slide 20: Specialty Division: Higher sales and prescription in Transplant
Specialty Division: Higher sales and prescription in Transplant Transplant Segment Ranked 1 in ORG Sales grew by 25 % to Rs 28 cr No 1 brand with 92 % market share. Change in KDIGO guidelines helped in prescription sales increase. Sales grew by 37 % to Rs 1.5 cr Sales grew by 38 % to Rs 4 cr 19
Slide 21: RPG LS: Increase in ONCO Therapy Prescription
RPG LS: Increase in ONCO Therapy Prescription • Sales of Frastim and Pegfrastim was Rs.2 Crs • Patient pool increased by 40 Sales of Azaplast was Rs 0.40 Crs Patient pool increased by 100 Sales of Arpimune was Rs 0.50 Crs Patient pool increased by 200 20
Slide 22: Way Forward: Specialty Division
Way Forward: Specialty Division Vision to be a dominate player in speciality, through product differentiation and patient service Relook to launch new Delivery mechanism with old molecules to Augment the Dialysis create better patient Portfolio with Bio compliance and better Revamp the Transplant si
Slide 23: RPGLS Specialty new product launches FY17
RPGLS Specialty new product launches FY 17 SOLID TUMOR HEMATOLOGY SUPPORTIVE THERAPY Rituximab Darbepoetin Anti Fungal MAB’s Anaemia 22
Slide 24: Cosmo-dermatology focused Glodiance Division planned
Cosmo-dermatology focused Glodiance Division planned RPGLS launching two research based products in Indian Cosmetic market in July’16. Product imported from Labo Italy. CRESCINA FILLERINA Therapy : Hair Re-growth Therapy : Anti-ageing Highlights: Highlights: • Stem cells activated hair regrowth • Fi
Slide 25: International Regulated Markets: Product Portfolio
International Regulated Markets: Product Portfolio Existing Products Products Under Development Azathioprine Nicorandil – EUCTD Lamotrigine (Tablet & OD) Sodium Valproate - EUCTD Mycophenolate Mofetil Amlodipine - EUCTD 24
Slide 26: Regulated Market: Key actions taken in FY16
Regulated Market : Key actions taken in FY 16 Successfully passed customer orders of Apotex and Tillomed which resulted in higher orders from these customers Received EU GMP certification for F 2 plant Developed new molecule Nicorandil and tied up with Amneal UK. Received GBP of 150000 from them Suc
Slide 27: Way Forward: International Formulations for FY17
Way Forward : International Formulations for FY 17 Strengthening leadership position of Azathioprine in global markets Penetrating more markets for Azathioprine in EU with multiple partners. Filing new products for registrations in EU and Latin America ROW – Grow existing business by smart outsourci
Slide 28: Table of Contents
Table of Contents RPG Group RPG LS : Overview, Performance and Strategic Direction RPG LS : Financials
Slide 29: RPG LS: Financial Performance Q2 and H1 FY17 (without Biotech)
RPG LS: Financial Performance Q2 and H 1 FY 17 (without Biotech) Rs crs Parameter Q2FY16 Q1 FY17 Q2FY17 QoQ YoY H1FY16 H1FY17 YoY Net Sales 62.38 79.01 76.38 -3% 22.4% 124.80 155.39 25% Raw Material 20.41 29.27 28.42 -3% 39.2% 42.71 57.69 35% Gross margin 41.97 49.74 47.96 -4% 14.3% 82.09 97.70 19%
Slide 30: RPG LS: Financial Performance Q2 and H1 FY17
RPG LS: Financial Performance Q2 and H 1 FY 17 Rs crs Parameter Q2FY16 Q1 FY17 Q2FY17 QoQ YoY H1FY16 H1FY17 YoY Net Sales 67.20 85.23 76.38 -10% 13.7% 133.70 161.61 21% Raw Material 22.44 30.70 28.36 (0.08) 26.4% 46.22 59.06 28% Gross margin 44.76 54.53 48.02 -12% 7.3% 87.48 102.55 17% Gross margin
Slide 31: Thank You
T H A N K Y O U
RPG Life Sciences — Investor Presentation (November 2016) on 6ix